Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma.
Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn JK, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Jain P, Frigault MM, Izumi R, Nguyen D, Patel P, Yin M, Długosz-Danecka M. Wang M, et al. Among authors: doorduijn jk. Leukemia. 2019 Nov;33(11):2762-2766. doi: 10.1038/s41375-019-0575-9. Epub 2019 Sep 26. Leukemia. 2019. PMID: 31558766 Clinical Trial. No abstract available.
Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study.
Bromberg JEC, Issa S, van der Holt B, van der Meulen M, Dirven L, Minnema MC, Seute T, Durian M, Cull G, van der Poel MWM, Stevens WBC, Zijlstra JM, Brandsma D, Nijland M, Mason KD, Beeker A, Abrahamse-Testroote MCJ, van den Bent MJ, de Jong D, Doorduijn JK. Bromberg JEC, et al. Among authors: doorduijn jk. Neuro Oncol. 2024 Apr 5;26(4):724-734. doi: 10.1093/neuonc/noad224. Neuro Oncol. 2024. PMID: 38037691 Free PMC article. Clinical Trial.
Clinical Impact of Polymerase Chain Reaction-Based Aspergillus and Azole Resistance Detection in Invasive Aspergillosis: A Prospective Multicenter Study.
Huygens S, Dunbar A, Buil JB, Klaassen CHW, Verweij PE, van Dijk K, de Jonge N, Janssen JJWM, van der Velden WJFM, Biemond BJ, Bart A, Bruns AHW, Haas PA, Demandt AMP, Oudhuis G, von dem Borne P, van der Beek MT, Klein SK, Godschalk P, Span LFR, Postma DF, Kampinga GA, Maertens J, Lagrou K, Mercier T, Moors I, Boelens J, Selleslag D, Reynders M, Zandijk W, Doorduijn JK, Cornelissen JJ, Schauwvlieghe AFAD, Rijnders BJA. Huygens S, et al. Among authors: doorduijn jk. Clin Infect Dis. 2023 Jul 5;77(1):38-45. doi: 10.1093/cid/ciad141. Clin Infect Dis. 2023. PMID: 36905147 Free PMC article.
Management of mantle cell lymphoma in the elderly patient.
Doorduijn JK, Kluin-Nelemans HC. Doorduijn JK, et al. Clin Interv Aging. 2013;8:1229-36. doi: 10.2147/CIA.S35082. Epub 2013 Sep 16. Clin Interv Aging. 2013. PMID: 24072968 Free PMC article. Review.
Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study.
Kater AP, Spiering M, Liu RD, Doreen Te Raa G, Slinger E, Tonino SH, Beckers MM, Daenen S, Doorduijn JK, Lankheet NA, Luijks DM, Eldering E, van Oers MH. Kater AP, et al. Among authors: doorduijn jk. Leuk Res. 2014 Jan;38(1):34-41. doi: 10.1016/j.leukres.2013.10.004. Epub 2013 Oct 28. Leuk Res. 2014. PMID: 24238639 Clinical Trial.
Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials.
Hoster E, Geisler CH, Doorduijn J, van der Holt B, Walewski J, Bloehdorn J, Ribrag V, Salles G, Hallek M, Pott C, Szymczyk M, Kolstad A, Laurell A, Räty R, Jerkeman M, Van't Veer M, Kluin-Nelemans JC, Klapper W, Unterhalt M, Dreyling M, Hermine O. Hoster E, et al. Leukemia. 2016 Jun;30(6):1428-30. doi: 10.1038/leu.2015.322. Epub 2015 Nov 24. Leukemia. 2016. PMID: 26598017 No abstract available.
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, Jurczak W. Wang M, et al. Lancet. 2018 Feb 17;391(10121):659-667. doi: 10.1016/S0140-6736(17)33108-2. Epub 2017 Dec 11. Lancet. 2018. PMID: 29241979 Free PMC article. Clinical Trial.
103 results